BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)’s share price traded down 9% on Tuesday . The company traded as low as $5.13 and last traded at $5.23. 3,873,319 shares changed hands during mid-day trading, an increase of 256% from the average session volume of 1,087,800 shares. The stock had previously closed at $5.75.
A number of equities analysts have weighed in on the company. BidaskClub raised BioCryst Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, August 25th. Noble Financial reissued a “buy” rating on shares of BioCryst Pharmaceuticals in a research report on Sunday, May 28th. Jefferies Group LLC raised BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating and boosted their target price for the stock from $5.00 to $7.00 in a research report on Wednesday, September 6th. Zacks Investment Research lowered BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, June 27th. Finally, HC Wainwright reissued a “buy” rating on shares of BioCryst Pharmaceuticals in a research report on Tuesday, August 8th. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and seven have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $9.13.
The firm’s market capitalization is $420.64 million. The company’s 50 day moving average is $4.84 and its 200-day moving average is $6.11.
BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.02). The business had revenue of $3.10 million during the quarter, compared to analyst estimates of $5.79 million. BioCryst Pharmaceuticals had a negative return on equity of 276.62% and a negative net margin of 160.97%. BioCryst Pharmaceuticals’s revenue was down 35.4% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.22) EPS. On average, equities research analysts expect that BioCryst Pharmaceuticals, Inc. will post ($0.75) earnings per share for the current fiscal year.
Several institutional investors have recently added to or reduced their stakes in BCRX. RA Capital Management LLC lifted its holdings in shares of BioCryst Pharmaceuticals by 47.9% during the second quarter. RA Capital Management LLC now owns 5,162,242 shares of the biotechnology company’s stock worth $28,702,000 after purchasing an additional 1,672,447 shares during the period. FMR LLC lifted its holdings in shares of BioCryst Pharmaceuticals by 114.5% during the second quarter. FMR LLC now owns 3,124,676 shares of the biotechnology company’s stock worth $17,373,000 after purchasing an additional 1,667,791 shares during the period. Vanguard Group Inc. lifted its holdings in shares of BioCryst Pharmaceuticals by 49.1% during the first quarter. Vanguard Group Inc. now owns 5,011,763 shares of the biotechnology company’s stock worth $42,098,000 after purchasing an additional 1,651,292 shares during the period. State Street Corp lifted its holdings in shares of BioCryst Pharmaceuticals by 72.0% during the second quarter. State Street Corp now owns 3,909,013 shares of the biotechnology company’s stock worth $21,736,000 after purchasing an additional 1,636,909 shares during the period. Finally, Bogle Investment Management L P DE acquired a new stake in shares of BioCryst Pharmaceuticals during the first quarter worth about $9,058,000. 86.23% of the stock is owned by hedge funds and other institutional investors.
WARNING: “BioCryst Pharmaceuticals, Inc. (BCRX) Stock Price Down 9%” was first posted by Markets Daily and is the property of of Markets Daily. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this news story can be read at https://www.themarketsdaily.com/2017/09/12/biocryst-pharmaceuticals-inc-bcrx-stock-price-down-9.html.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.
Receive News & Ratings for BioCryst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.